Kymera Therapeutics Statistics
Share Statistics
Kymera Therapeutics has 64.77M shares outstanding. The number of shares has increased by 15.06% in one year.
| Shares Outstanding | 64.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 55.01M |
| Failed to Deliver (FTD) Shares | 144 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 9.16M, so 14.15% of the outstanding shares have been sold short.
| Short Interest | 9.16M |
| Short % of Shares Out | 14.15% |
| Short % of Float | 16.7% |
| Short Ratio (days to cover) | 24.12 |
Valuation Ratios
The PE ratio is -10.11 and the forward PE ratio is -16.08.
| PE Ratio | -10.11 |
| Forward PE | -16.08 |
| PS Ratio | 18.91 |
| Forward PS | 40.3 |
| PB Ratio | 3.76 |
| P/FCF Ratio | -10.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Kymera Therapeutics Inc. has an Enterprise Value (EV) of 1.46B.
| EV / Earnings | -9.94 |
| EV / Sales | 18.59 |
| EV / EBITDA | -10.2 |
| EV / EBIT | -8.82 |
| EV / FCF | -10.64 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.21.
| Current Ratio | 4.73 |
| Quick Ratio | 4.73 |
| Debt / Equity | 0.21 |
| Total Debt / Capitalization | 17.65 |
| Cash Flow / Debt | -1.21 |
| Interest Coverage | -844.54 |
Financial Efficiency
Return on equity (ROE) is -0.37% and return on capital (ROIC) is -34.51%.
| Return on Equity (ROE) | -0.37% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -34.51% |
| Revenue Per Employee | 427.13K |
| Profits Per Employee | -798.71K |
| Employee Count | 184 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 60.97% in the last 52 weeks. The beta is 2.22, so Kymera Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.22 |
| 52-Week Price Change | 60.97% |
| 50-Day Moving Average | 46.19 |
| 200-Day Moving Average | 41.37 |
| Relative Strength Index (RSI) | 40.21 |
| Average Volume (20 Days) | 441.46K |
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of $78.59M and earned -$146.96M in profits. Earnings per share was $-2.52.
| Revenue | 78.59M |
| Gross Profit | -110.49M |
| Operating Income | -165.53M |
| Net Income | -146.96M |
| EBITDA | -143.20M |
| EBIT | -165.53M |
| Earnings Per Share (EPS) | -2.52 |
Balance Sheet
The company has $109.97M in cash and $84.67M in debt, giving a net cash position of $25.29M.
| Cash & Cash Equivalents | 109.97M |
| Total Debt | 84.67M |
| Net Cash | 25.29M |
| Retained Earnings | -530.75M |
| Total Assets | 1.03B |
| Working Capital | 502.18M |
Cash Flow
In the last 12 months, operating cash flow was -$102.83M and capital expenditures -$34.48M, giving a free cash flow of -$137.31M.
| Operating Cash Flow | -102.83M |
| Capital Expenditures | -34.48M |
| Free Cash Flow | -137.31M |
| FCF Per Share | -2.35 |
Margins
Gross margin is -140.59%, with operating and profit margins of -210.62% and -186.99%.
| Gross Margin | -140.59% |
| Operating Margin | -210.62% |
| Pretax Margin | -186.99% |
| Profit Margin | -186.99% |
| EBITDA Margin | -182.21% |
| EBIT Margin | -210.62% |
| FCF Margin | -174.71% |
Dividends & Yields
KYMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6% |
| FCF Yield | -5.05% |
Analyst Forecast
The average price target for KYMR is $56, which is 33.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $56 |
| Price Target Difference | 33.4% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Scores
| Altman Z-Score | 11.16 |
| Piotroski F-Score | 4 |